This article was originally published in Start Up
Beta inverse agonists, also known as beta blockers, have always been considered excellent therapy for hypertension, but not so excellent for asthma. They have a reputation for impressive short-term efficacy, but at great expense: namely, an unfortunate tendency to worsen asthmatic conditions over time. Inverseon Inc., however, doesn't see that as an inevitability. In fact, the company claims its lead product, a beta-adrenergic inverse agonist called INV102, has beneficial effects on asthma with long-term use.
You may also be interested in...
Asthma represents one of the blockbuster markets in the pharmaceutical industry; sales of drugs from 10 companies amount to $14 billion each year. Yet despite the high-volume sales of asthma drugs, in 73% of patients the disease is poorly controlled. For pharmaceutical firms and start-ups, the complex, multifactorial disease offers tantalizing possibilities; it's an enormous, yet underserved market with many points of entry, mechanistically speaking.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.